+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Sclerosis (Scleroderma) Disease - Global Clinical Trials Review, H2, 2020

  • ID: 5233944
  • Clinical Trials
  • December 2020
  • Region: Global
  • 293 pages
  • GlobalData

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc
  • Novartis AG
Summary

The publisher's clinical trial report, “Systemic Sclerosis (Scleroderma) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Systemic Sclerosis (Scleroderma) Clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Sclerosis (Scleroderma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The publisher Clinical Trial Reports are generated using the publisher’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Kadmon Holdings Inc
  • Novartis AG
Report Guidance
  • Clinical Trials Report Coverage
Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
  • In Progress Trials by Phase
Clinical Trials by Trial Status

Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials
Prominent Drugs

Clinical Trial Profile Snapshots

Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About the Publisher
  • Contact
  • Source
List of Tables
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Region, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, North America, Top Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020*
  • Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, G7 Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, E7 Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Systemic Sclerosis (Scleroderma) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
List of Figures
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Region (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020*
  • Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, G7 Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
  • Proportion of Systemic Sclerosis (Scleroderma) to Immunology Clinical Trials, E7 Countries (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Phase (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics, Global, Clinical Trials by Trial Status, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, by End Point Status, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019
  • Systemic Sclerosis (Scleroderma) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
  • Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
  • Methodology
Note: Product cover images may vary from those shown
  • Johnson & Johnson
  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sanofi
  • GlaxoSmithKline Plc
  • United Therapeutics Corp
  • C. H. Boehringer Sohn AG & Co KG
  • Kadmon Holdings Inc
  • Plus Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll